30 closest matches · ranked by relevance
Knee Osteoarthritis · Degenerative Joint Disease of Knee
Primary: Number of Participants Experiencing Treatment-related Adverse Events, as a Measure of Safety — 1; 7; 2 Participants
Prostatic Hyperplasia, Benign · Enlarged Prostate With Lower Urinary Tract Symptoms
Primary: Number of Participants With Adverse Events — 3 Participants
Osteoarthritis
Primary: Percentage Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Pain Score — -50.1 Percentage change
Trauma to the Spleen
Primary: Number of Participants Who Were Enrolled Within 18 Months of Study Initiation — 23; 23 Participants
Benign Prostatic Hyperplasia (BPH)
Primary: The Primary Objective is to Evaluate the Safety of Prostate Artery Embolization (PAE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign…
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptoms
Primary: Long-term Effectiveness of Prostatic Artery Embolization (PAE) With Embosphere Microspheres as Assessed by the International Prostate Symptom Score (IPSS). — -11.1…
Morbid Obesity
Primary: Percent Weight Change — 11.5 percentage of excess weight loss
Enlarged Prostate
Primary: Time for Prostatic Artery Catheterization — 273.40; 181.71; 206.38; 155.96 seconds
Knee Osteoarthritis
Primary: Change in KOOS Pain Score — 33 score on a scale — p=0.00041
Benign Prostatic Hyperplasia
Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants
Hepatocellular Carcinoma · Liver Cancer · Hepatoma
Primary: Response to Treatment by RECIST Criteria — 3; 3; 48; 47 Participants
Benign Prostatic Hyperplasia
Primary: Number of Adverse Events Reported — 7 adverse events
Uterine Fibroid · Arteriovenous Malformations · Hypervascular Tumors
Primary: Procedural Success — 70; 16; 7; 6 Participants
Benign Prostatic Hyperplasia (BPH)
Primary: Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . — 6; 10; 0; 0 events — p=0.05
Neuroendocrine Tumor · Islet Cell Tumor
Primary: Percentage of Participants With Progression Free Survival (PFS) at 12 Months — 66 percentage of participants
Leiomyoma
Primary: Pain Scores Using the VAS Questionnaire — 0.8; 1.3; 4; 6.1 score on a scale
Colorectal Carcinoma
Primary: Freedom From Serious Adverse Events Rate — 18 Participants
Peripheral Arterial Hemorrhage
Primary: Percentage of Participants With Composite of Freedom From Major Adverse Events (MAEs) — 100 percentage of participants — p=<0.025
Embolization, Therapeutic
Primary: Technical Success — 55 Target Embolization Sites
Arterial Embolization · Other Surgical Procedures · Obesity
Primary: Body Weight Average 6 Months Post-Procedure — 237.6 lbs.
Osteo Arthritis Knee
Primary: Mean WOMAC Scores at Month 6 — 29; 26 units on a scale
Uveal Melanoma · Liver Metastases
Primary: Response of Liver Metastases — 0; 0; 5; 3 participants
BPH
Primary: Mean Change in IPSS Score — -11.4 units on a scale
Hepatocellular Carcinoma
Primary: Freedom From Serious Adverse Event (SAE) at 30days — 22 participants
Hemorrhage · Bleeding Hemorrhage
Primary: Number of Participants With Clinical Success: Cessation of Bleeding up to 24 Hours — 100 Participants
Aortic Valve Stenosis
Primary: Number of Participants With Procedural Success — 14 Participants
Cancer of Liver
Primary: Patients Survival (Safety) — 12 Participants
Hypervascular Tumor and Arteriovenous Malformation
Primary: Success Rate of Embolization in the Target Vessel — 100; 96.4 Percentage of participants
Obesity, Morbid
Primary: Weight Loss — 2.8; 6.4; 1.8; 8.3 Percent change
Osteoarthritis Of Knee
Primary: Patient Function (Units on a Scale) — 31 units on a scale